http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110407876-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 2019-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110407876-B |
| titleOfInvention | A kind of febuxostat and phosphocreatine derivative and preparation method thereof and use in preparing anti-cardiomyocyte injury medicine |
| abstract | The invention belongs to the field of biomedicine and discloses a febuxostat and phosphocreatine derivative, a preparation method thereof, and use in preparing an anti-cardiomyocyte injury drug. The derivative has the structure shown in formula (I). The use of febuxostat and phosphocreatine derivatives in the preparation of anti-cardiomyocyte injury drugs is disclosed for the first time, and the invention discloses that the compound can become a promising innovative drug candidate compound; its source compound, febuxostat Both creatine phosphate and creatine phosphate are clinically proven drugs. This drug has a wide range of sources, low price, strong pharmacological effects and high safety. It belongs to the transformation of old drugs into new drugs, and provides an economical and safe drug choice for the majority of cardiovascular disease patients. . |
| priorityDate | 2019-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 105.